Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership.

Bookmark this %label%

Psoriasis impacts the health and psychosocial functioning of patients, conferring a significant economic burden on healthcare systems. There remain unmet needs in psoriasis care, which if addressed by research, could […]

» Read more

fJoint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

Bookmark this %label%

Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and […]

» Read more

Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.

Bookmark this %label%

Multiple biologics for psoriasis exist and interleukin (IL)-17 inhibitors are among those with best efficacy. However, switching treatment is often required at some point and intraclass switch of IL-17 inhibitors […]

» Read more

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.

Bookmark this %label%

The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to better inform treatment decisions and specifically, to inform guideline development.We […]

» Read more

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

Bookmark this %label%

Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.Plaque psoriasis is the most common […]

» Read more

Treatment of erythrodermic psoriasis with biologics: A systematic review.

Bookmark this %label%

Biologic medications for plaque psoriasis have been used to treat erythrodermic psoriasis (EP). Since the guidelines for management of EP were published, new biologics have been approved for the treatment […]

» Read more

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update.

Bookmark this %label%

The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), […]

» Read more

Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies.

Bookmark this %label%

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world’s population. In this guideline, we focus the discussion on systemic, non-biologic medications for […]

» Read more

Association of herpes zoster and chronic inflammatory skin disease in United States inpatients.

Bookmark this %label%

Patients with chronic inflammatory skin diseases (CISD) have potential risk factors for herpes zoster (HZ). Yet, little is known about HZ risk in CISD.Determine whether CISD is associated with HZ.Data […]

» Read more

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.

Bookmark this %label%

Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management […]

» Read more

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS).

Bookmark this %label%

Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis.To compare efficacy and safety of guselkumab with fumaric acid esters (FAE) in systemic […]

» Read more

Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council.

Bookmark this %label%

Abstract: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity […]

» Read more

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.

Bookmark this %label%

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population. In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet light-based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents (PUVA), targeted UVB treatments like excimer laser, and several other modalities and variations of these core phototherapies, including newer applications of pulsed dye laser, intense pulse light, and light emitting electrodes. We will provide an in-depth, evidence-based discussion of efficacy and safety for each treatment modality and provide recommendations and guidance for the use of these therapies alone or in conjunction with other topical and/or systemic psoriasis treatments.

» Read more

Complete Skin Clearance and PASI response rates in clinical practice- Predictors, Health Related Quality of Life improvements and implications for treatment goals.

Bookmark this %label%

PASI90 is suggested to be the new standard endpoint RCTs of biologics for psoriasis, whereas treatment guidelines often still refer to PASI75.To analyse in a real-world setting: Firstly, what factors are associated with higher levels of treatment response to biologics. Secondly, the Health-Related Quality of Life gains associated with different response levels in clinical practice.Biologically-naïve patients with PASI, DLQI and EQ-5D outcomes before (maximum 6 months) and after (3-12 months) switch to biologics during registration in the Swedish Register for systemic treatment of psoriasis, PsoReg, were included (n=515). Patient characteristics associated with higher treatment response were analysed by regression analyses. Improvements in absolute PASI, DLQI and EQ-5D were assessed in different PASI percent response levels.High PASI percentage response was associated with higher PASI before switch and lower BMI. DLQI and EQ-5D improved within all responder groups (p<0·001). The magnitude of improvements in DLQI (p=0·02) differed between responder groups. The mean (SD) DLQI improvement for PASI75-<90, PASI90-<100 responders and patients achieving Complete Skin Clearance (PASI100) were 9·9 (7·4), 11·5 (7·0) and 8·0 (6·1), respectively.PASI percentage change is largely dependent on absolute PASI before switch. Patients in clinical practice lack "baseline" PASI values as they may switch directly from one treatment to another or stay successfully treated for a longer time period. Treatment goals such as PASI90 are thus not suitable for treatment guidelines or for follow-up in clinical practice. This article is protected by copyright. All rights reserved.

» Read more

Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society).

Bookmark this %label%

This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non-biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque-psoriasis, which was summarized in Tables ad-hoc. The main end-points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0-1 and significant improvement of health-related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE: direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers.

» Read more

Measuring Psoriatic Arthritis Symptoms, A Core Domain in Psoriasis Clinical Trials.

Bookmark this %label%

Abstract: The International Dermatology Outcome Measures (IDEOM) established a set of core domains to be measured in all psoriasis trials. This set indicates that symptoms of psoriatic arthritis (PsA) should […]

» Read more

Management of Pediatric Plaque Psoriasis using Biologics.

Bookmark this %label%

Abstract: Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect both adults and children. In adults, biologics have revolutionized the treatment of moderate to severe […]

» Read more